Adverse reactions during biological drug therapy in psoriasis: Clinical series and a review of the literature

Giornale Italiano di Dermatologia e Venereologia

Volumn 146, Issue 4, 2011, Pages 273-281

  Montesu, M A ^a   Addis, G M ^a   Satta, R ^a   Cottoni, F ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Biological therapy; Drug toxicity; Psoriasis

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; BRONCHOPNEUMONIA; CANDIDIASIS; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ERYTHRODERMA; FEMALE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; KERATITIS; MALE; NAIL INFECTION; PSEUDOMONAS INFECTION; PSORIASIS; PSORIATIC ARTHRITIS; RASH; RESPIRATORY TRACT DISEASE; SKIN INFLAMMATION; URINARY TRACT INFECTION;

EID: 80755182378     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Bos JD, De Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005;152:1098-107. (Pubitemid 40933406)
2. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003;17:257-70. (Pubitemid 36575644)
3. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000;9:1511-22. (Pubitemid 30433711)
4. Krueger G. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4. (Pubitemid 32240779)
5. Cush JJ. Safety of new biological therapies in rheumatoid arthritis. Bullet Rheum Dis 2003;52.
6. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-75. (Pubitemid 39071656)
7. Day R. Adverse reactions to TNF-alpha blockers in rheumatoid arthritis. Lancet 2002;359:540-1. (Pubitemid 34178431)
8. Thielen AM, Kuenzli S, Saurat JH. Cutaneous adverse event of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209-17. (Pubitemid 41415860)
9. Poulin Y, Papp KA, Carey W, Gulliver W A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence. J Cutan Med Surg 2006;9(Suppl 1):10-7.
10. Gaylor ML, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol 2004;3:77-9.
11. Lowes MA, Turton JA, Krueger JG, Barnetson RS. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol 2005;18:5-9.
12. Gisondi P, Giglio MD, Girolomoni G. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study. J Dermatolog Treat 2006;17:172-5. (Pubitemid 44147837)
13. Bukhari IA. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation. Saudi Med J 2007;28:1745-7. (Pubitemid 350237995)
14. Hernandez Garcia I. Severe erythroderma in a patient under intermittent therapy with efalizumab. J Drugs Dermatol 2008;7:987-9.
15. Lowes MA, Chamian F, Abello MV, Leonardi C, Dummer W, Papp K et al. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatol 2007;26:2.
16. Antonucci A, Bardazzi F, Balestri R, Patrizi A. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases. J Dermatolog Treat 2009;20:61-2.
17. Balato A, La Bella S, Gaudiello F, Balato N. Efalizumab-induced guttate psoriasis. Successful management and re-treatment. J Dermatolog Treat 2008;19:182-4. (Pubitemid 351883003)
18. Ulmer A, Wölbing F, Metzler G, Schanz S, Fierlbeck G, Röcken M. Severe exacerbation of chronic plaque psoriasis following initially effective therapy with efalizumab: clinical characterization and therapeutic management. Br J Dermatol 2008;158:867-9. (Pubitemid 351415751)
19. Adişen E, Gürer MA. Plantar exfoliation and desquamation during efalizumab therapy. J Eur Acad Dermatol Venereol 2008;22:633-4. (Pubitemid 351541071)
20. Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report. Acta Derm Venereol 2006;86:456-7. (Pubitemid 44450109)
21. De Groot M, De Rie MA, Bos JD. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris. Br J Dermatol 2005;153:843-4.
22. Firmin D, Roguedas AM, Lemasson G, Abgrall JF, Misery L. Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects. Dermatology 2008;217:203-6.
23. Durox H, Sparsa A, Loustand-Ratti V, Prey S, Gondran G, Manea P et al. Efalizumab-induced lupus-like syndrome. Acta Derm Venereol 2008;88:270-1. (Pubitemid 351743872)
24. Rallis E, Tapinis P, Verros CD. Efalizumab-induced hypertrichosis. Br J Dermatol 2008;158:1158-9. (Pubitemid 351521465)
25. Klein A, Szeimies RM, Andthaler M, Karrer S. Exacerbation of pityriasis rubra pilaris under efalizumab therapy. Dermatology 2007;215:72-5. (Pubitemid 46976019)
26. Tom WL, Miller MD, Hurley MY, Suneja T, Kudva G, Leonardi CL et al. Efalizumab-induced autoimmune pancytopenia. Br J Dermatol 2006;155:1045-7. (Pubitemid 44564518)
27. Hostetler SG, Zirwas M, Bechtel MA. Efalizumab-associated thrombocytopenia. J Am Acad Dermatol 2007;57:707-10. (Pubitemid 47384932)
28. Fargnoli MC, Tabilio A, Coletti G, Peris K. Efalizumab-induced immune thrombocytopenia during retratment. J Am Acad Dermatol 2008;58(5 suppl 1):S125-7.
29. Nosbaum A, Allombert-Blaise C, Ly A, Jullien D, Faure M, Claudy A et al. Efalizumab-induced pancytopenia. Ann Dermatol Venereol 2008;135:407-8.
30. Thachil J, Marteew V. Thrombotic thrombocytopenic purpura with the use of efalizumab for psoriasis. Br J Dermatol 2008;158:1138-9. (Pubitemid 351521425)
31. Kwan JM, Reese AM, Trafeli JP. Delayed autoimmune hemolitic anemia in efalizumab-treated psoriasis. J Am Acad Dermatol 2008;58:1053-5.
32. Bommakanti S, Patil A, Eshoa C, Chitambar CR. Case reports: efalizumab-associated lymphoproliferative disease. J Drugs Dermatol 2007;6:646-8.
33. Caudron A, Lok C, Clabaut A, Desblache J, Heyman B, Viseux V. Cytomegalovirus colitis in a patient treated with efalizumab. Dermatology 2009;218:84-5.
34. Balato A, Balato N, Patruno C, Gallo L, Ayala F. Visceral leishmaniasis infection in a patient with psoriasis treated with Efalizumab. Dermatology 2008;217:360-1.
35. Tuxen AJ, Yong MK, Street AC, Dolianitis C. Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and Ciclosporin. Br J Dermatol 2007;157:1067-8. (Pubitemid 47583519)
36. Weisenseel P, Kuznetsov AV, Flaig M, Prinz JC. Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy. Dermatology 2008;217:85-6. (Pubitemid 351896578)
37. Kluger N, Girard C, Gonzalez V, Guillot B, Bessis D. Efalizumab-induced aseptic meningitis. Br J Dermatol 2007;156:189-91.
38. Rivas-Rodriguez R, Romero-Alonso MM, Gabella-Bazarot E, Sanchez-Gomez E. Efalizumab-induced aseptic meningitis. Famm Hosp 2007;31:70-1.
39. Morse LG, Yarbrough L, Hogan DJ. Cervical cancer in a woman associated with long-term efalizumab therapy. J Am Acad Dermatol 2005;53:354-5. (Pubitemid 40979602)
40. White JM, SmithCH, Robson A, Ash G, Barker JN. DRESS syndrome caused by efalizumab. Clin Exp Dermatol 2008;33:50-2. (Pubitemid 350308541)
41. Cid Conde L, Silveria Cancela D. Rhabdomyolysis probably caused by interaction between efalizumab and pravastatin. Farm Hosp 2007;31:135-6. (Pubitemid 47013972)
42. Santos-Juanes J, Coto-Segura P, Mallo S, Galache C, Soto J. Multiple eruptive dermatofibromas in a patient receiving efalizumab. Dermatology 2008;216:363. (Pubitemid 351630106)
43. Papadavid E, Makris M, Dalamaga M, Kalogeromitros D, Stavrianeas N. Recall injection-site reactions to etanercept in a patient with psoriasis. Clin Exp Dermatol 2009;34:414-5.
44. Clelland S, Hunek JR. Etanercept injection site reaction. Dermatol Nurse 2005;17:375.
45. Bathelier E, Gunera-Saad N, Berard F, Nicolas JF. Angiokeratoma induced by injection of etanercept for psoriasis. J Am Acad Dermatol 2008;59(5 Suppl):S124-5.
46. Sun G, Wasko CA, Hsv S. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. J Drugs Dermatol 2008;7:69-71.
47. Gonzalo-Garijo MA, Perez-Calderon R, de Argila Fernandez-Duran D. Severe generalized exanthema due to etanercept given for severe plaque psoriasis. Ann Allergy Asthma Immunol 2008;100:621-2. (Pubitemid 351829868)
48. Daulat S, Detweiler JG, Pandya AG. Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol 2009;23:483-4.
49. Winter UM, Treudler R, Paasch U, Sticherling M, Simon JC. A case of granulomatous rosacea coinciding with the use of etanercept no relapse with infliximab. Hautarzt 2008;59:724-7.
50. Bovenschen HJ, Kop EN, Van De Kerkhof PC, Seyger MM. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatolog Treat 2006;17:381-3. (Pubitemid 46895585)
51. De Simone C, Caldarola G, D'Agostino M, Rotoli M, Capizzi R, Amerio P. Lichenoid reaction induced by Adalimumab. J Eur Acad Dermatol Venereol 2008;22:626-7. (Pubitemid 351541066)
52. Newell EL, Jain S, Stephens C, Martland G. Infliximab-induced pityriasis lichenoides chronica in a patient with psoriasis. J Eur Acad Dermatol Venereol 2009;23:230-1.
53. Costa LA, Belinchòn J, Betlloch I, Perez-Crespo M, Mataix J. Multiple lentigines arising in resolving psoriatic plaques after treatment with etanercept. Dermatol Online J 2008;14:11.
54. Santos-Juanes J, Cito P, Mallo S, Galache C, Sanchez del Rio J, Torre JC. Multiple lentigines confined to resolving psoriatic plaques in a patient treated with adalimumab. Dermatology 2008;216:279. (Pubitemid 351416734)
55. George SJ, Anderson HL, HSU S. Adalimumab-induced urticaria. Dermatol Online J 2006;12:4.
56. Vestergaard C, Deleuran M, Kragballe K. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol 2007;21:1272-4. (Pubitemid 47423430)
57. Dumont-Berset M, Laffitte E, Gerber C, Dudler J, Panizzon RG. Eczematous drug eruption after infliximab. Br J Dermatol 2004;151:1272-3.
58. Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol 2008;58(2Suppl):S50-2.
59. Goulão J, Cunha H, Anes I, Bàrtolo E, Furtado C, Serrano P et al. Urticarial vasculitis due do infliximab. J Eur Acad Dermatol Venereol 2008;22:882-3.
60. Antoniou C, Kosmadaki MG, Stratigos AI, Katsambas AD. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008;216:364-5. (Pubitemid 351630107)
61. Vinter H, Nielsen HI. Legionella pneumonia in patients treated with Infliximab. Ugeskr Laeger 2009;171:247.
62. Petersen B, Lorentzen H. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab. Acta Derm Venereol 2008;88:523-4.
63. Eisendle K, Fritsch P. Fatal fulminant legionnaires' disease in a patient with severe erytrodermis psoriasis treated with Infliximab after long-term steroid therapy. Br J Dermatol 2005;152:585-6. (Pubitemid 40547147)
64. Becart S, Segaert S. Recurrent varicella in an adult psoriasis patient treated with etanercept. Dermatology 2008;217:260-1.
65. Levy MS, Polsky D, Davidson A, Strober BE. Tinea versicolor associated with etanercept therapy. J Am Acad Dermatol 2008;58(5 Suppl 1):S99-100.
66. Ahmad K, Rogers S. Development of Crohn disease in a patient on etanercept for psoriasis. Br J Dermatol 2007;157:396. (Pubitemid 47083854)
67. Wahie S, Alexandroff A, Reynolds NS. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 2006;31:460-1.
68. Lee A, Kasama R, Evangelisto A, Elfenbein B, Falarca G. Henoch-Schönlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 2006;12:249-51. (Pubitemid 44527045)
69. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, Staveley-O'Carroll K, Billingsley EM, Marks JG, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007,56(5 Suppl):S65-7. (Pubitemid 46552081)
70. Comte C, Guilhon JJ, Guillot B, Dereure O. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology 2008;217:284-5.
71. Fryrear RS 2nd, Wiggins AK, Sanqueza O, Yosipovitch G. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad dermatol 2004;51:1026. (Pubitemid 39593030)
72. Ly L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol 2007;157:1076-8. (Pubitemid 47583529)
73. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007;157:1275-7. (Pubitemid 350115684)
74. Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 2006;54:160-4. (Pubitemid 41832480)
75. Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol 2005;53(5 Suppl 1):S260-2. (Pubitemid 41443484)
76. El-Hag K, Dercken HG, Prenzel R, Hölzle E. Drug-induced alveolitis associated with infliximab/azathioprine therapy. Pneumologie 2008;62:204-8.
77. Scheinfeld N. Menorrhagia and severe menstrual pain related to the use of adalimumab in a psoriatic. J Dermatolog Treat 2008;19:188-9. (Pubitemid 351883005)
78. Wu JJ, Tsai TF. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol 2008;144:1403-4.
79. Lahbabi I, Adamski H, Le Jean S, Cannieux V, Polard E, Chevrant-Breton J. Neutropenia and thrombocytopenia in a patient presenting psoriasis treated with etanercept. Ann Dermatol Venereol 2008;135:409-10.
80. De Oliveira JP, Levy A, Morel P, Guibal F. Severe neutrophilia induced by infliximab for psoriasis. Br J Dermatol 2008;158:200-1. (Pubitemid 350221928)
81. Mahè E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with Ciclosporin and infliximab. Br J Dermatol 2003;149:170-3. (Pubitemid 36966529)
82. Bachmeyer C, Thiolière B, Khosrotehrani K, Cattan E. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 2007;56:169-70. (Pubitemid 44969294)
83. Nair B, Raval G, Mehte P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022-4. (Pubitemid 350004395)
84. Girard C, Guillot B, Bessis D. Gastric MALT Lymphoma in a patient receiving infliximab for psoriasis. Br J Dermatol 2008;159:497-8. (Pubitemid 352009855)
85. Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Bérard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol 2007;17:546-7. (Pubitemid 350207176)
86. Wellington K, Perry CM. Efalizumab. Am J Clin 2004;22:427-35.
87. Pugliatti M, Riise T, Sotgiu MA, Sotgiu S, Satta WM, Mannu L et al. Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia. Neuroepidemiology 2005;25:129-34. (Pubitemid 41207065)
88. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.The effect of TNFalpha blockadeon the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005;14:931-7. (Pubitemid 43088266)
89. MGssner R, SchPn MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Cl Dermatol 2008;26:486-502.